ASCO 2025 | Phase III trial of catequentinib in pretreated leiomyosarcoma

Robin Jones • 1 Jun 2025

ASCO 2025

Sarcoma Catequentinib

Robin Jones, MBBS, MRCP, MD, Institute of Cancer Research, London, UK, discusses a Phase III trial (NCT03016819) of catequentinib in patients with advanced or metastatic leiomyosarcoma requiring third-line or later treatment. Catequentinib significantly improved progression-free survival compared to placebo, with consistent benefit observed in those with fewer prior therapies. Common treatment-related adverse events included gastrointestinal symptoms, fatigue, and hypertension. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.